27 April 2026
Latham & Watkins Advises Ascendis Pharma on Nasdaq Ordinary Share Listing
Advising firms
Deal team
9 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| John Williams Lead | Latham & Watkins LLP | Partner | corporate | Bay Area |
| Mark Roeder Lead | Latham & Watkins LLP | Partner | corporate | Bay Area |
| Paul Lau | Latham & Watkins LLP | Associate | corporate | Not stated |
| Keran Huang | Latham & Watkins LLP | Associate | corporate | Not stated |
| Taleah Tyrell | Latham & Watkins LLP | Associate | corporate | Not stated |
| Elena Romanova | Latham & Watkins LLP | Partner | tax | New York |
| Ethan Lee | Latham & Watkins LLP | Not stated | tax | Not stated |
| Maj Vaseghi | Latham & Watkins LLP | Partner | compensation and benefits | Bay Area |
| Ryan Gold | Latham & Watkins LLP | Partner | convertible notes | New York |
6 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- Not stated
- Counterparties
- Ascendis Pharma A/S (Issuer)